Article

Disinfectant Linked With Reduced Hospital-Onset Clostridioides difficile Infection

Author(s):

Hospital ward cleaning with potassium peroxymonosulphate-based environmental disinfectant and a decrease in days of therapy with carbapenems were associated with a reduction in the rate of hospital-onset Clostridioides difficile infection.

Hospital ward cleaning with potassium peroxymonosulphate-based environmental disinfectant (PPED) and a decrease in days of therapy with carbapenems were associated with a reduction in the rate of hospital-onset Clostridioides difficile infection (CDI), according to study findings published in the Journal of Hospital Infection.

The diarrhea-causing pathogen Clostridioides difficile has been linked with potentially life-threatening damage to the colon. The hospital setting’s long-standing presence of endospores has been indicated to contribute to nosocomial outbreaks of CDI, in which frequent use of broad-spectrum antimicrobials, such as carbapenems, fluoroquinolones, and third or fourth generation cephalosporin serve as risk factors.

“Antimicrobial stewardship (AS) can be used to reduce hospital-onset CDI. PPED is used in hospital environments as a countermeasure against infection with multi-drug resistant bacteria, norovirus and SARS-CoV-2, and has been used in many medical facilities in Japan under certain conditions,” said the study authors.

“A 1% PPED produces sodium hypochlorite when combined with sodium chloride, which functions as a disinfectant. However, little is known about the effect of hospital cleaning with PPED on hospital-onset CDI.”

Researchers conducted a retrospective, single-center study at the Tosei General Hospital in Aichi, Japan, to evaluate the impact of promoting antimicrobial stewardship and hospital ward cleaning with PPED on hospital-onset CDI.

The ratio of hospital-onset CDI, PPED consumption, and days of therapy of broad-spectrum antimicrobials were assessed between July 2014 and March 2018, in which this time was divided into prepromotion (July 2014 to June 2015) and post-promotion periods (July 2015 to March 2018).

From the prepromotion to the post-promotion period, hospital-onset CDI significantly decreased from 13.5 (interquartile range [IQR], 11.8-15.0) to 6.94 (IQR, 5.00-9.25), PPED consumption increased from 84.0 (IQR, 75.4-85.6) to 135.7 (IQR, 114.8-151.4), and days of therapy of carbapenems significantly decreased from 63.0 (IQR, 59.5-68.2) to 41.4 (IQR, 36.0-47.6). Use of other antimicrobials, including broad-spectrum antimicrobials, did not increase or decrease significantly.

Using interrupted time series analysis, an immediate significant change was observed (P = .03) after intervention, but no downward trend in hospital-onset CDI was observed over this period (slope change, 0.09 to –2.78; P = 0.19). Trends in PPED consumption significantly changed over this period (P = .02) and days of therapy of carbapenems decreased immediately after the intervention began (P < .01).

Regarding variables affecting the ratio of hospital-onset CDI, Poisson regression analysis findings showed that PPED consumption (incidence rate ratio [IRR], 0.886; 95% CI, 0.790-0.994; P = .039) and days of therapy of carbapenems (IRR, 1.025; 95% CI, 1.005-1.046; P = .016) were independent factors.

As the first study reporting the impact of hospital ward cleaning with PPED on the reduction of hospital-onset CDI, researchers concluded that subsequent multicenter prospective intervention studies are warranted to confirm findings.

Reference

Umemura T, Mutoh Y, Masayuki M, et al. Impact of hospital environmental cleaning with a potassium peroxymonosulphate-based environmental disinfectant and antimicrobial stewardship on the reduction of hospital-onset Clostridioides difficile infections. ​​J Hosp Infect. 2022 Jul 9;S0195-6701(22)00219-5. doi:10.1016/j.jhin.2022.06.018

Related Videos
Dr Cesar Davila-Chapa
Milind Desai, MD
Masanori Aikawa, MD
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Screenshot of an interview with Ruben Mesa, MD
Ruben Mesa, MD
Screenshot of Susan Wescott, RPh, MBA
Screenshot of Stephanie Hsia, PharmD
Screenshot of an interview with Megan Ehret, PharmD
Cesar Davila-Chapa, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo